In Situ Vaccination for the Treatment of Cancer
- 9 February 2016
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 8 (3) , 315-330
Abstract
Vaccination has had a tremendous impact on human health by harnessing the immune system to prevent and eradicate infectious diseases and this same approach might be used in cancer therapy. Cancer vaccine development has been slowed hindered by the paucity of universal tumor-associated antigens and the difficulty in isolating and preparing individualized vaccines ex vivo. Another approach has been to initiate or stimulate an immune response in situ (at the tumor site) and thus exploit the potentially numerous tumor-associated antigens there. Here, we review the many approaches that have attempted to accomplish effective in situ vaccination, using intratumoral administration of immunomodulators to increase the numbers or activation state of either antigen present cells or T cells within the tumor.Keywords
This publication has 141 references indexed in Scilit:
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in CancersMolecular Therapy, 2012
- A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic MelanomaMolecular Therapy, 2011
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceCancer Immunology, Immunotherapy, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Potentiating Cancer Immunotherapy Using an Oncolytic VirusMolecular Therapy, 2010
- Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent mannersCancer Immunology, Immunotherapy, 2010
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With AdenovirusMolecular Therapy, 2009
- Arming parvoviruses with CpG motifs to improve their oncosuppressive capacityInternational Journal of Cancer, 2008
- Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirusProceedings of the National Academy of Sciences, 2006